Date: 2016-09-22
Type of information: Series A financing round
Company: iOmx Therapeutics (Germany)
Investors: Merck Ventures (Germany) MPM Capital (USA - MA) Sofinnova Partners (France) Wellington Partners (UK)
Amount: € 40 million
Funding type: series A financing round
Planned used: iOmx has been founded in March 2016 based on the work of its scientific founders Philipp Beckhove and Nisit Khandelwal conducted at the German Cancer Research Center. The company focuses on the development of first-in-class cancer therapeutics addressing novel immune checkpoints on cancer cells. The company’s proprietary platform systematically screens tumor cells for specific immune checkpoint modulators, which allow targeting the tumor´s immune resistance mechanisms. By systematically screening human tumor cells, the company has already identified a number of new targets and analyzed their mode of action.The proceeds of this series A financing round will be used to advance several proprietary product candidates up to initial clinical proof-of-concept.
Others: * On September 22, 2016, iOmx Therapeutics announced the closing of a Series A financing round totaling € 40 million. MPM Capital and Sofinnova Partners co-led the round, and were joined by Wellington Partners and Merck Ventures.
Therapeutic area: Cancer - Oncology
